Ena Respiratory

Ena Respiratory is aiming to transform the treatment and prevention of respiratory infections in at-risk populations
Ena Respiratory
Operating

Ena Respiratory is developing a novel class of synthetic, topically delivered innate immunomodulators that have the capability to prime the immune system in the respiratory tract and prevent the complications associated with respiratory viral infections. The company is based in Melbourne, Australia and it has secured a Series A investment from the Brandon Capital managed Medical Research Commercialisation Fund (MRCF) and Uniseed. The company is based in Melbourne, Australia and it has secured a Series A investment from the Brandon Capital managed Medical Research Commercialisation Fund (MRCF) and Uniseed.

Investors
Investor

Medical Research Commercialisation Fund (MRCF)

Investor

Uniseed Ventures

 Location
Melbourne
 People
No information available.
 Tags
#medical research
#medtech
 Feedback